Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUEEN-OSCAR: QL1706 + Olaparib in HRD+ HER2- Breast Cancer
NCT07113964Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free Survival at 3 years. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07113964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113964.